The FDA approval and early launch metrics for Lumvoa are the primary catalysts. Monitor weekly prescription data and payer coverage decisions over the next 2-3 quarters to gauge revenue trajectory. The strong cash position removes near-term dilution risk, but the widening net loss and high SG&A burn warrant attention to commercial execution.
Price Chart
Executive Summary
Viridian Therapeutics reported Q2 2026 results highlighting the FDA approval and U.S. launch of Lumvoa (veligrotug-vvze) for thyroid eye disease on June 26, 2026, ahead of its PDUFA date. The company posted a net loss of $127.1M, wider than the $100.7M loss in Q2 2025, driven by a $55.0M SG&A expense as it built commercial infrastructure for the launch. Cash, cash equivalents, and marketable securities stood at $981.5M after a $394M convertible debt and equity financing in May 2026, providing runway through profitability.
Key Financial Metrics
Key Facts
- Lumvoa (veligrotug-vvze) was FDA-approved on June 26, 2026, ahead of the PDUFA target date, and immediately launched in the U.S.
- First doses of Lumvoa were administered in July 2026; patient enrollment forms indicate broad and strong physician demand.
- Field sales team achieved engagement with 95% of the 2,000 core prescribing physicians with strong early feedback.
- Completed convertible debt and equity financing in May 2026 with gross proceeds of $394 million.
- Cash, cash equivalents, and marketable securities were $981.5M as of June 30, 2026, up from $762.2M as of March 31, 2026.
- Net loss for Q2 2026 was $127.1M, compared to $100.7M in Q2 2025.
- Elegrobart BLA submission on track for Q1 2027; TSHR IND submission anticipated in Q4 2026.
- VRDN-008 phase 1 healthy volunteer data expected in 2H 2026.
Financial Impact
Net loss widened to $127.1M from $100.7M YoY; SG&A surged to $55.0M from $20.2M due to commercial build-out for Lumvoa launch. Cash position strengthened to $981.5M after $394M financing.
Risk Factors
- Lumvoa commercial launch may underperform if payer coverage is slow or physician adoption stalls.
- Net loss is widening as SG&A expenses ramp; profitability timeline depends on Lumvoa revenue scaling.
- Elegrobart BLA submission in Q1 2027 and subsequent approval are not guaranteed; pipeline setbacks could pressure the stock.
- Competition from existing TED treatments (e.g., Tepezza) may limit market share.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-336691 |
| Document: d174744d8k.htm | 0001193125-26-336691 |
| Document: 0001193125-26-336691-index-headers.html | 0001193125-26-336691 |
| Document: 0001193125-26-336691-index.html | 0001193125-26-336691 |
| Document: 0001193125-26-336691.txt | 0001193125-26-336691 |
| 8-K Data (Synthetic) | 0001193125-26-336691 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 11w ago | 8-K | $22.51 $22.96 | ▲ +2.00% | ▲ +1.40% | $23.82 (+5.80%) |
May 28, 2026 21w ago | 8-K | $17.62 $18.79 | ▲ +6.64% | ▲ +8.43% | $23.82 (+35.16%) |
May 26, 2026 21w ago | 8-K | $17.26 $17.39 | ▲ +0.75% | ▲ +2.65% | $23.82 (+37.98%) |
May 8, 2026 24w ago | 424B5 | $17.20 $16.31 | ▲ +5.17% | ▲ +4.87% | $23.82 (−38.46%) |
May 5, 2026 24w ago | 424B5 | $17.53 $16.35 | ▼ −6.73% | ▼ −9.51% | $23.82 (+35.85%) |
May 5, 2026 25w ago | 8-K | $18.75 $15.87 | ▼ −15.36% | ▼ −20.31% | $23.82 (+27.01%) |
Apr 17, 2026 27w ago | DEFA14A | $14.80 $17.43 | ▲ +17.77% | ▲ +12.40% | $23.82 (+60.91%) |
Feb 26, 2026 34w ago | 8-K | $29.49 $28.20 | ▼ −4.37% | ▲ +2.03% | $23.82 (−19.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers